These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 28694704)

  • 21. An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
    Messana JA; Schwartz SS; Townsend RR
    Vasc Health Risk Manag; 2017; 13():43-54. PubMed ID: 28255241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are older patients satisfied with physician assistants and nurse practitioners?
    Cipher DJ; Hooker RS; Sekscenski E
    JAAPA; 2006 Jan; 19(1):36, 39-40, 42-4. PubMed ID: 16433221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.
    Prasanna Kumar KM; Ghosh S; Canovatchel W; Garodia N; Rajashekar S
    Indian J Endocrinol Metab; 2017; 21(1):196-209. PubMed ID: 28217522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes.
    Nigro SC; Riche DM; Pheng M; Baker WL
    Ann Pharmacother; 2013 Oct; 47(10):1301-11. PubMed ID: 24259694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.
    Davies MJ; Merton K; Vijapurkar U; Yee J; Qiu R
    Cardiovasc Diabetol; 2017 Mar; 16(1):40. PubMed ID: 28327140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors Influencing the Prescribing Preferences of Physicians for Drug-Naive Patients with Type 2 Diabetes Mellitus in the Real-World Setting in Japan: Insight from a Web Survey.
    Murayama H; Imai K; Odawara M
    Diabetes Ther; 2018 Jun; 9(3):1185-1199. PubMed ID: 29696567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK.
    Evans M; Achha S; Neslusan C
    Diabetes Ther; 2017 Oct; 8(5):1175-1185. PubMed ID: 28948541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Choosing a Provider: What Factors Matter Most to Consumers and Patients?
    Kozikowski A; Morton-Rias D; Mauldin S; Jeffery C; Kavanaugh K; Barnhill G
    J Patient Exp; 2022; 9():23743735221074175. PubMed ID: 35083376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.
    Tang H; Dai Q; Shi W; Zhai S; Song Y; Han J
    Diabetologia; 2017 Oct; 60(10):1862-1872. PubMed ID: 28725912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fracture Risk Assessment in Patients With Diabetes Mellitus.
    Poiana C; Capatina C
    J Clin Densitom; 2017; 20(3):432-443. PubMed ID: 28716499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fracture risk associated with common medications used in treating type 2 diabetes mellitus.
    Wolverton D; Blair MM
    Am J Health Syst Pharm; 2017 Aug; 74(15):1143-1151. PubMed ID: 28743778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review: Dapagliflozin increases, and empagliflozin reduces, adverse renal events in type 2 diabetes.
    Nguyen JT; Molony DA
    Ann Intern Med; 2017 Jul; 167(2):JC5. PubMed ID: 28715827
    [No Abstract]   [Full Text] [Related]  

  • 34. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
    Blau JE; Tella SH; Taylor SI; Rother KI
    Diabetes Metab Res Rev; 2017 Nov; 33(8):. PubMed ID: 28736981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Durability of response to dapagliflozin: a review of long-term efficacy and safety.
    Jabbour S
    Curr Med Res Opin; 2017 Sep; 33(9):1685-1696. PubMed ID: 28699798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes.
    Pratley RE; Cersosimo E
    Clin Diabetes; 2017 Jul; 35(3):141-153. PubMed ID: 28761216
    [No Abstract]   [Full Text] [Related]  

  • 37. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.
    Nomoto H; Miyoshi H; Sugawara H; Ono K; Yanagiya S; Oita M; Nakamura A; Atsumi T
    Diabetol Metab Syndr; 2017; 9():54. PubMed ID: 28725273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus.
    Molugulu N; Yee LS; Ye YT; Khee TC; Nie LZ; Yee NJ; Yee TK; Liang TC; Kesharwani P
    Diabetes Res Clin Pract; 2017 Oct; 132():157-168. PubMed ID: 28797524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus.
    Cazarim MS; da Cruz-Cazarim ELC; Baldoni AO; Dos Santos TBE; de Souza PG; Silva IA; Rodrigues RNR; Maia ACFC; Pereira LRL; Sanches C
    Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S859-S865. PubMed ID: 28701284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.